Your browser doesn't support javascript.
loading
Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma.
Breitkreutz, I; Raab, M S; Vallet, S; Hideshima, T; Raje, N; Mitsiades, C; Chauhan, D; Okawa, Y; Munshi, N C; Richardson, P G; Anderson, K C.
Affiliation
  • Breitkreutz I; Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Iris_Breitkreutz@dfci.harvard.edu
Leukemia ; 22(10): 1925-32, 2008 Oct.
Article in En | MEDLINE | ID: mdl-18596740
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoclasts / Thalidomide / Bone Remodeling / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoclasts / Thalidomide / Bone Remodeling / Multiple Myeloma / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Leukemia Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2008 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido